Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
A Phase I, double- blinded, randomized, placebo- controlled study to test the safety of LMSCs in Adults suffering from mild to severe acute respiratory distress syndrome (ARDS) due to COVID-19 resultant from 2019-nCoV coronavirus infection, or resultant from influenza virus infection.
Description: Incidence of treatment-emergent serious adverse events (TE-SAEs) within 4 weeks after treatment, defined as one or more of the following untoward medical occurrences happening within the first 4 weeks after treatment. i. Life-threatening event (e.g., stroke or non-fatal pulmonary embolism). ii. Event requiring inpatient hospitalization or prolongation of existing hospitalization (e.g., for worsening dyspnea). iii. Event resulting in persistent or significant disability/incapacity. iv. Event resulting in death. v. Event leading to other clinically significant untoward laboratory test result(s) or medical condition(s), as determined by the Investigator.
Measure: Incidence of Treatment-Emergent Serious Adverse Events Time: Within 4 weeks after treatmentDescription: Number of Participants with Abnormal Clinical Significant Lab Values in the Hematology testing will be assessed at Baseline and 6 Months.
Measure: Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology. Time: Baseline to 6 MonthsDescription: Overall Assessment Normal vs Abnormal will be collected at Baseline and 6 months, this change in overall assessment will be the outcome in numbers of particants with a change.
Measure: Number of Participants with Changes in Echocardiography Overall Assessment Time: Baseline to 6 MonthsDescription: Number of Participants with changes to Overall Assessment Normal vs Abnormal will be collected at Baseline and 6 Months
Measure: Number of Participants with Changes to overall assessment of Electrocardiogram Time: Baseline to 6 MonthsDescription: Time to recovery of Sp02 to 90% or higher on room air (or the oxygen concentration the patient had before acute illness) after 10 minutes of spontaneous breathing.
Measure: Time to recovery of Sp02 Time: Baseline to 6 MonthsDescription: Number of Participants with Abnormal Clinical Significant Lab Values in Blood Chemistry testing will be assessed at Baseline and 6 Months.
Measure: Number of Participants with Abnormal Clinical Significant Lab Values in the Blood Chemistry testing. Time: Baseline to 6 monthsDescription: Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation testing will be assessed at Baseline and 6 Months.
Measure: Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation. Time: Baseline to 6 monthsDescription: Number of Participants with Abnormal Clinical Significant Lab Values in the Hematology testing will be assessed at Baseline and 6 Months.
Measure: Number of Participants with Abnormal Clinical Significant Lab Values in the Urinalysis Time: Baseline to 6 monthsDescription: Geometric mean titer
Measure: Immunity Time: Baseline to 6 MonthsDescription: Change in overall assessment via Lung imaging via chest X-ray will be assessed and compared between baseline and 6 months
Measure: Change in Imaging via X-ray Time: Baseline to 6 MonthsDescription: Change in overall assessment via Lung imaging via computerized tomography will be assessed and compared between baseline and 6 months
Measure: Change in Imaging via Computerized Tomography Time: Baseline to 6 MonthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports